Perrin C White1. 1. UT Southwestern Medical Center, Professor of Pediatrics, Dallas, Texas, USA.
Abstract
PURPOSE OF REVIEW: Although the basic treatment of congenital adrenal hyperplasia (CAH) is well established, there are active clinical research projects to more closely mimic the normal diurnal rhythm of cortisol secretion and to reduce total glucocorticoid doses to minimize adverse metabolic effects. RECENT FINDINGS: We review clinical studies on CAH treatment published in the last 18 months or currently underway according to ClinicalTrials.gov listings. These can be grouped into several broad themes: alternative dosing forms of hydrocortisone with altered pharmacokinetics or easier dose titration; corticotropin-releasing hormone receptor antagonists that reduce corticotropin (ACTH) secretion and thereby reduce adrenal androgen secretion; androgen biosynthesis inhibitors; a first clinical trial of a gene therapy vector. SUMMARY: Alternative dosing forms of hydrocortisone are, or will shortly be, marketed, but cost may be a barrier to utilization, at least in the US market. Trials of corticotropin releasing hormone receptor antagonists and androgen biosynthesis inhibitors are currently underway. The author believes that trials of gene therapy for CAH are premature.
PURPOSE OF REVIEW: Although the basic treatment of congenital adrenal hyperplasia (CAH) is well established, there are active clinical research projects to more closely mimic the normal diurnal rhythm of cortisol secretion and to reduce total glucocorticoid doses to minimize adverse metabolic effects. RECENT FINDINGS: We review clinical studies on CAH treatment published in the last 18 months or currently underway according to ClinicalTrials.gov listings. These can be grouped into several broad themes: alternative dosing forms of hydrocortisone with altered pharmacokinetics or easier dose titration; corticotropin-releasing hormone receptor antagonists that reduce corticotropin (ACTH) secretion and thereby reduce adrenal androgen secretion; androgen biosynthesis inhibitors; a first clinical trial of a gene therapy vector. SUMMARY: Alternative dosing forms of hydrocortisone are, or will shortly be, marketed, but cost may be a barrier to utilization, at least in the US market. Trials of corticotropin releasing hormone receptor antagonists and androgen biosynthesis inhibitors are currently underway. The author believes that trials of gene therapy for CAH are premature.
Authors: Sandra Markmann; Bishnu P De; Jasmine Reid; Clarisse L Jose; Jonathan B Rosenberg; Philip L Leopold; Stephen M Kaminsky; Dolan Sondhi; Odelya Pagovich; Ronald G Crystal Journal: Hum Gene Ther Date: 2018-03-20 Impact factor: 5.695
Authors: Claudia Weiß; Andreas Ziegler; Lena-Luise Becker; Jessika Johannsen; Heiko Brennenstuhl; Gudrun Schreiber; Marina Flotats-Bastardas; Corinna Stoltenburg; Hans Hartmann; Sabine Illsinger; Jonas Denecke; Astrid Pechmann; Wolfgang Müller-Felber; Katharina Vill; Astrid Blaschek; Martin Smitka; Lieske van der Stam; Katja Weiss; Benedikt Winter; Klaus Goldhahn; Barbara Plecko; Veronka Horber; Günther Bernert; Ralf A Husain; Christian Rauscher; Regina Trollmann; Sven F Garbade; Andreas Hahn; Maja von der Hagen; Angela M Kaindl Journal: Lancet Child Adolesc Health Date: 2021-10-29
Authors: Julie A Hutt; Basel T Assaf; Brad Bolon; Joy Cavagnaro; Elizabeth Galbreath; Branka Grubor; Lisa M Kattenhorn; Annette Romeike; Laurence O Whiteley Journal: Toxicol Pathol Date: 2021-10-17 Impact factor: 1.902
Authors: Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White Journal: Endocr Rev Date: 2022-01-12 Impact factor: 19.871
Authors: Deborah P Merke; Ashwini Mallappa; Wiebke Arlt; Aude Brac de la Perriere; Angelica Lindén Hirschberg; Anders Juul; John Newell-Price; Colin G Perry; Alessandro Prete; D Aled Rees; Nicole Reisch; Nike Stikkelbroeck; Philippe Touraine; Kerry Maltby; F Peter Treasure; John Porter; Richard J Ross Journal: J Clin Endocrinol Metab Date: 2021-04-23 Impact factor: 5.958
Authors: Adina F Turcu; Ashwini Mallappa; Aikaterini A Nella; Xuan Chen; Lili Zhao; Aya T Nanba; James Brian Byrd; Richard J Auchus; Deborah P Merke Journal: Front Endocrinol (Lausanne) Date: 2021-11-16 Impact factor: 5.555